�Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) announced that the company has developed a gel-like form of Oxycyte� that it intends to investigate as a topical lotion for open wounds, abrasions and nathan Birnbaum. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic o carrier.
The innovation is based on technologies in-licensed earlier this year from Virginia Commonwealth University. In combination with a atomic number 1 peroxide pouch, researchers believe the compound could have superior abilities to rescue a senior high school concentration of oxygen directly to the wounded tissue. The combination of Oxycyte gel and H2O2 is believed to be the key to its possible efficacy. The company intends to defer to the FDA a protocol for a proposed clinical probe before the end of the calendar year.
"Unlike the intravenous drug applications programme of Oxycyte in traumatic brain injury, this would be a topical diligence, applied to the skin or to the surface of wounds. So we're hopeful that the clinical review treat would be as a medical twist, which can be shorter and faster than review as a drug," said company chairperson and CEO Chris J. Stern, DBA. "If the safety/efficacy cps is indeed shorter, as I trust it can be, and so it suggests that substantial partnering models could be launched shortly after refuge and efficacy are proved. Sales of ointments, dressings, bandages, etc are counted in the high billions of dollars each twelvemonth. I think that every one of these products could prove to be a candidate to post a anatomy of Oxycyte.
"While I'm excited about this new potential habit for Oxycyte, I know that the big question on our shareholders' minds right now is the status of our Phase IIb protocol for Oxycyte in TBI. We're non going to get into the details of our communications with the FDA. That would not be in the best interests of the company or the process. I'll just say that positive communications are continuing and that when there is news, we'll declare it," said Stern.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and aesculapian devices in the field of atomic number 8 therapeutics and continuous substrate monitoring. The Company has under development a pFC therapeutic atomic number 8 carrier and liquid ventilating system product and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarct, surgery, injury, malignant tumors and diabetes. For further information, visit http://www.oxybiomed.com.
Caution Regarding Forward-Looking Statements
This news release contains certain modern statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include references to potential wound care applications of Oxycyte in treating open wounds, abrasions and george Burns and to expectations that the FDA will permit clinical trials and reviews to be conducted as a medical device rather than a drug. Forward-looking statements in this release also include those that suggest markets in which a injury care edition of Oxycyte could be used and estimates of the accumulative size of those markets. Actual events or results may take issue from the company's expectations. There tin can be no assurance that the FDA will approve a protocol to carry on clinical trials for these applications, that it testament allow examination and review as a medical device, and that if conducted, any clinical trials will be successful or that the FDA will approve use of Oxycyte in any formulation in the uses described in this release. Furthermore, there can be no assurance that if the FDA does approve such uses that the production will compete successfully or that sales at any meaningful levels will be reached. There can be no assurance also that the company will be able to reach or launch whatever partnering agreements to acquire and/or market these applications of Oxycyte. Additional info concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can buoy be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via http://www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intention or duty to update these advanced statements beyond the appointment of this release. This caution is made under the safe harbor provender of the Private Securities Litigation Reform Act of 1995.
Oxygen Biotherapeutics, Inc.
More info
Friday, 5 September 2008
Subscribe to:
Posts (Atom)